62 related articles for article (PubMed ID: 17083342)
41. Tumor lysis syndrome (TLS) following fludarabine therapy for chronic lymphocytic leukemia (CLL): case report and review of the literature.
Hussain K; Mazza JJ; Clouse LH
Am J Hematol; 2003 Mar; 72(3):212-5. PubMed ID: 12605395
[TBL] [Abstract][Full Text] [Related]
42. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches.
Morrison VA
Best Pract Res Clin Haematol; 2010 Mar; 23(1):145-53. PubMed ID: 20620978
[TBL] [Abstract][Full Text] [Related]
43. Extrapulmonary tuberculous abscess in chronic lymphocytic leukaemia (CLL) treated with fludarabine: case report and review of literature.
Leung WH; Tsang SF; Chim CS
Am J Hematol; 2005 Jul; 79(3):246-7. PubMed ID: 15981223
[No Abstract] [Full Text] [Related]
44. The changing paradigm of chronic lymphocytic leukemia management.
Lobetti-Bodoni C; Bertoni F; Stussi G; Cavalli F; Zucca E
Eur J Intern Med; 2013 Jul; 24(5):401-10. PubMed ID: 23583413
[TBL] [Abstract][Full Text] [Related]
45. Clinical challenges in chronic lymphocytic leukemia.
O'Brien S
Semin Hematol; 1998 Jul; 35(3 Suppl 3):22-6. PubMed ID: 9685176
[No Abstract] [Full Text] [Related]
46. Oral fludarabine therapy in chronic lymphocytic leukemia--increased convenience.
Boogaerts MA
Hematol J; 2004; 5 Suppl 1():S31-7. PubMed ID: 15079151
[TBL] [Abstract][Full Text] [Related]
47. Infectious complications of chronic lymphocytic leukemia.
Wadhwa PD; Morrison VA
Semin Oncol; 2006 Apr; 33(2):240-9. PubMed ID: 16616071
[TBL] [Abstract][Full Text] [Related]
48. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis.
Morrison VA
Clin Lymphoma Myeloma; 2009 Oct; 9(5):365-70. PubMed ID: 19858055
[TBL] [Abstract][Full Text] [Related]
49. The infectious complications of chronic lymphocytic leukemia.
Morrison VA
Semin Oncol; 1998 Feb; 25(1):98-106. PubMed ID: 9482531
[TBL] [Abstract][Full Text] [Related]
50. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.
Plunkett W; Gandhi V; Huang P; Robertson LE; Yang LY; Gregoire V; Estey E; Keating MJ
Semin Oncol; 1993 Oct; 20(5 Suppl 7):2-12. PubMed ID: 8235690
[TBL] [Abstract][Full Text] [Related]
51. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis.
Zhu Q; Tan DC; Samuel M; Chan ES; Linn YC
Leuk Lymphoma; 2004 Nov; 45(11):2239-45. PubMed ID: 15512812
[TBL] [Abstract][Full Text] [Related]
52. A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia.
Tadmor T; Welslau M; Hus I
Expert Rev Hematol; 2018 Jan; 11(1):57-70. PubMed ID: 29160119
[TBL] [Abstract][Full Text] [Related]
53. Current therapies for chronic lymphocytic leukemia: risk and prophylaxis strategies for secondary/opportunistic infections.
Diella L; Bavaro DF; Loseto G; Pasciolla C; Minoia C; Di Gennaro D; Belati A; De Candia MS; Di Gennaro F; Saracino A; Guarini A
Expert Rev Hematol; 2023 Apr; 16(4):267-276. PubMed ID: 37012253
[TBL] [Abstract][Full Text] [Related]
54. A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia.
Randhawa JK; Ferrajoli A
Expert Rev Hematol; 2016 Mar; 9(3):235-44. PubMed ID: 26652692
[TBL] [Abstract][Full Text] [Related]
55. Infectious complications in chronic lymphoid malignancy.
Egerer G; Hensel M; Ho AD
Curr Treat Options Oncol; 2001 Jun; 2(3):237-44. PubMed ID: 12057123
[TBL] [Abstract][Full Text] [Related]
56. Challenges in ocular infectious diseases and the evolution of anti-infective therapy.
Olson RJ
Surv Ophthalmol; 2004 Mar; 49 Suppl 2():S53-4. PubMed ID: 15028479
[No Abstract] [Full Text] [Related]
57. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.
Eichhorst BF; Busch R; Schweighofer C; Wendtner CM; Emmerich B; Hallek M;
Br J Haematol; 2007 Jan; 136(1):63-72. PubMed ID: 17083342
[TBL] [Abstract][Full Text] [Related]
58. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
59. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
